Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population

Abstract The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination, however, real world evidence...

Full description

Bibliographic Details
Main Authors:	Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-08-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-95758-1

Similar Items

HER2 positive mucinous carcinoma of breast with micropapillary features: Report of a case and review of literature
by: Dinesh Chandra Doval, et al.
Published: (2021-09-01)

Sorafenib-induced hand-foot syndrome
by: Chaturbhuj Agrawal, et al.
Published: (2017-01-01)

Primary pulmonary melanoma: An unexpected diagnosis
by: Chaturbhuj Ramanand Agrawal, et al.
Published: (2018-01-01)

Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder
by: Manish Sharma, et al.
Published: (2020-10-01)

Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma
by: Dinesh Chandra Doval, et al.
Published: (2014-01-01)

Only 9 weeks or complete 12 months of adjuvant trastuzumab in Indian early-stage breast cancer patients: Is it the practice-changing approach in a resource-constrained setting?
by: Chaturbhuj R Agrawal, et al.
Published: (2020-01-01)

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
by: Raffaella Palumbo, et al.
Published: (2021-03-01)

A rare case of lung adenocarcinoma: Unusual presentation with miliary mottling
by: Pankaj Goyal, et al.
Published: (2020-01-01)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
by: Katie Mycock, et al.
Published: (2021-01-01)

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
by: Dinesh Chandra Doval, et al.
Published: (2013-01-01)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
by: Bardia, A., et al.
Published: (2022)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
by: Tremblay G, et al.
Published: (2018-05-01)

Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01)

Palbociclib in breast cancer neoadjuvant setting
by: Sílvia Alexandra Cabral Duarte, et al.
Published: (2021-08-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Determination of palbociclib by high performance liquid chromatography
by: Xiaodong SHI, et al.
Published: (2017-08-01)

Profile of palbociclib in the treatment of metastatic breast cancer
by: Ehab M, et al.
Published: (2016-05-01)

Folfox encephalopathy: A rare case series
by: Ullas Batra, et al.
Published: (2017-01-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
by: M. A. Frolova, et al.
Published: (2018-07-01)

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
by: Ballestrero, A., et al.
Published: (2022)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
by: Luc Cabel, et al.
Published: (2020-09-01)

Design and synthesize of novel Palbociclib derivatives as AMPK activators
by: Chen-Chen Huang, et al.
Published: (2018)

Population Pharmacokinetics of Palbociclib in aReal-World Situation
by: Bernard Royer, et al.
Published: (2021-02-01)

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
by: Kellie Lynn Nelson, et al.
Published: (2017-07-01)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
by: Atakan Demir, et al.
Published: (2020-03-01)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain
by: Galve-Calvo E, et al.
Published: (2018-11-01)

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
by: Yi Li, et al.
Published: (2021-06-01)

Broncho-biliary fistula secondary to biliary obstruction and lung abscess in a patient with pancreatic neuro-endocrine tumor
by: Dipanjan Panda, et al.
Published: (2016-06-01)

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice
by: L. G. Zhukova, et al.
Published: (2019-06-01)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
by: Sushmita Rath, et al.
Published: (2021-01-01)

Progress with palbociclib in breast cancer: latest evidence and clinical considerations
by: Andrea Rocca, et al.
Published: (2017-02-01)

Updates on managing advanced breast cancer with palbociclib combination therapy
by: Teresa M. McShane, et al.
Published: (2018-08-01)

Oral ulcers in patients treated with palbociclib: a case report
by: Alande Cédric, et al.
Published: (2018-06-01)

Distraction Osteogenesis Using a Monolateral External Fixator for Infected Non-Union of the Femur with Bone Loss
by: Sumit Arora, et al.
Published: (2012-08-01)

Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience
by: Boér K, et al.
Published: (2021-07-01)

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
by: Luis Manso, et al.
Published: (2020-12-01)

Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung
by: Ullas Batra, et al.
Published: (2018-01-01)

Mucosal gastric metastases: A very rare site of metstasis from germ cell tumour
by: Pankaj Goyal, et al.
Published: (2015-01-01)

Cannot write session to /tmp/vufind_sessions/sess_9rt8114ccgu7epkecjhthqvh35